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Abstract 
Presently, India bears amongst the highest burden of non-communicable diseases such as 
diabetes mellitus (DM), hypertension (HT), and cardio vascular disease (CVD) and thus 
represents a vulnerable target to the SARS-CoV-2/COVID-19 pandemic. Involvement of the 
angiotensin converting enzyme 2 (ACE2) in susceptibility to infection and pathogenesis by 
SARS-CoV-2 is currently an actively pursued research area. An increased susceptibility to 
infection in individuals with DM, HT and CVD together with higher levels of circulating ACE2 
in these settings presents a scenario where interaction with soluble ACE2 may result in 
disseminated virus-receptor complexes that could enhance virus acquisition and pathogenesis. 
Thus, understanding the SARS-CoV-2 receptor binding domain-ACE2 interaction, both 
membrane bound and in the cell free context may contribute to elucidating the role of co-
morbidities in increased susceptibility to infection and pathogenesis. Both Azithromycin and 
Hydroxychloroquine (HCQ) have shown efficacy in mitigating viral carriage in infected 
individuals. Furthermore, each of these compounds generate active metabolites which in turn 
may also modulate virus-receptor interaction and thus influence clinical outcomes. In this 
study, we model the structural interaction of S1 with both full-length and soluble ACE2. 
Additionally, therapeutic drugs and their active metabolites were docked with soluble ACE2 
protein. Our results show that S1 from either of the reported Indian sequences can bind both 
full-length and soluble ACE2, albeit with varying affinity that can be attributed to a reported 
substitution in the RBD. Furthermore, both Azythromycin and HCQ together with their active 
metabolites can allosterically affect, to a range of extents, binding of S1 to ACE2. 
 
Key Words: ACE2, Azithromycin, Co-morbidities Indian Sequences, Hydroxychloroquine,  
SARS-CoV-2 spike protein 1, Structural Studies 
2 
 
Introduction 
Coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) pandemic has impacted around 1.7 million people with more 
than 10000 deaths from 210 countries across the globe so far (Zhu N et al, 2020; ; CSSE, Johns 
Hopkins University). As of 11th April 2020, India  has 6565 active cases,  239 deaths with 642 
individuals who have been documented to have recovered (Ministry of Health and Family 
Welfare, Government of India; https://www.mohfw.gov.in/). All these figures are expected to 
escalate rapidly. Several clinical and epidemiological studies reporting on COVID-19 have 
linked comorbidities such as diabetes (DM), hypertension (HT) and cardiovascular disease 
(CVD) with increased risk of infection leading to increased mortality (Guan W et al, 2020; 
Fang L et al, 2020). Angiotensin converting enzyme 2 (ACE2), the receptor for SARS-CoV-2, 
is widely expressed by several organs including the oral mucosa, lung, intestine, kidney, blood 
vessels, and on immunoreactive cells (Zou X et al, 2020). Elevated levels of ACE2 could 
potentially result in increased susceptibility to infection by SARS-CoV-2 (Xu H et al, 
2020). Patients with DM, HT and CVD, which seem to be the most common comorbidities in 
patients with COVID-19, are typically treated with drugs that inhibit the renin-angiotensin 
system (RAS), including angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin 
receptor blockers (ARBs). RAS inhibitors are very commonly used not only for management 
of blood pressure but also for protection from disease-associated inflammation and organ 
remodelling (Simoes ESAC et al, 2016). A consequence of this therapy, increased levels of 
ACE2, including its cell-free soluble form are observed in these individuals (Vuille-dit-Bille 
RN et al, 2015; Hoffmann M et al, 2020). The high proportion of patients with severe COVID-
19 and these comorbidities prompted us to probe the molecular mechanism by which SARS- 
CoV-2 attaches and interacts with membrane bound and cell free forms of ACE2. 
At present, a combination of two known drugs namely Azithromycin and Hydroxychloroquine 
(HCQ) are promising therapeutic interventions used for management of COVID-19 patients 
(Gautret P et al, 2020). Direct and potentially competitive effects of these drugs with virus-
receptor interaction have heretofore been unexplored.  Thus, in this study we investigated the 
potential interaction of the drugs Azithromycin and HCQ together with their active metabolites 
and biologically relevant forms of ACE2 to provide structural insights that would help in 
understanding the increased pathogenesis in these high risk individuals. 
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Materials and Methods 
Multiple sequence alignment 
SARS-CoV-2spike protein 1 (S1) for Indian sequence 1 (INS1; Yadav P, et al., 2020; Acc. No. 
MT050493), 2 (INS2; Yadav P, et al., 2020; Acc. No. MT012098.1), Wuhan SARS-CoV-2 (Wu 
F, et al., 2020; Acc. No. QHD43416) and SARS-CoV ( He R, et al., 2018; NP-828851.1) were 
downloaded from NCBI database for multiple sequence alignment to identify potential indels 
and substitutions between these four protein sequences using CLUSTAL-Omega tool (Fabian 
Sievers et al, 2011). We performed two multiple sequence alignments; the first alignment 
comprised of INS1, INS2 and Wuhan SARS-CoV-2 and the second multiple sequence 
alignment comprised of INS1, INS2, Wuhan SARS-CoV-2 and SARS-CoV sequences. 
Homology modelling 
The ACE2 protein of Homo sapiens was downloaded from Uniprot database with an Accession 
Number: Q9BYF1 (Bairoch A, 1996). This protein sequence is made up of 805 amino acids 
(aa) which is classified into extracellular domain (aa 18-740); helical domain (aa 741-761) and 
cytoplasmic domain (aa 792-805). In particular, the interface regions aa 30-41; aa 82-84 and 
aa 353-357 were preferred by S1 for protein-protein interaction. The circulating soluble form 
of ACE2 (sACE2) without the membrane anchor has been reported in blood (Batlle D et al, 
2020). Apart from the full length ACE2, sACE2 without the transmembrane region with 
residues ranging from 18-708 has also been reported in PTM/Processing- Uniprot database. 
Protein Data Bank (PDB) search was done for identification of potential structural templates 
for both complete and sACE2. The crystal structure of ACE2 was available in PDB (PDB ID: 
6m18) but with many missing residues (Berman H, 2000; Yan R et al, 2020). Therefore, 
homology modelling of the ACE2 protein sequence of Homo sapiens using SWISS-MODEL 
server was opted (Waterhouse A et al, 2018). From the modelled ACE2 protein, the complete 
and sACE2 was generated for further analysis. The two reported S1 sequences for Indian 
SARS-CoV-2 (INS1 and INS2) were downloaded from NCBI. Both these sequences were 
modelled using SWISS-MODEL online server. Finally, modelled ACE2 and S1 from INS1 
and INS2 were considered for structure validation using PROCHECK-Ramachandran plot 
server (Laskowski R A et al, 1993). Modelled ACE2, INS1 and INS2 3D structures were 
energy minimized using CHIMERA software (Pettersen E et al, 2004). 
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Protein-Protein docking 
Both complete and sACE2 were considered for Protein-Protein docking with receptor binding 
domain (RBD) from S1 of INS1 and INS2 using HADDOCK server (G.C.P van Zundert et al, 
2016). For docking purpose, the active and passive residues were obtained through literature 
survey. Active residues associated with ACE2 included residues within the range of aa 30-41, 
aa 82-84 and aa 353-357 which were obtained from Uniprot Database.  
Regarding the active residues for S1, the complete RBD was considered which included 
residues from aa 319-541. Within this region lies the receptor binding motif (RBM) (aa 437-
508). The residues critically involved in receptor interaction were identified through literature 
review (Tai W et al, 2020; Lan J et al, 2020). Passive residues were defined automatically 
through the check box for ACE2 and S1 from INS1 and INS2. In total, four docking 
experiments were performed which comprised of complete ACE2 with S1 from INS1 and INS2 
and sACE2 with S1 from INS1 and INS2. For every run, HADDOCK software generated 10 
clusters of four poses each, along with the HADDOCK score, buried surface area and energy 
details. Of these, the cluster with least HADDOCK score was considered for their binding 
energy analysis using PRODIGY server for all the four docking experiments (Vangone A et al, 
2019). Furthermore, the docked poses were generated using CHIMERA software (Pettersen E 
et al, 2004). Hydrogen bonding analysis was carried out using Discovery Studio Visualizer 
(Discovery Studio 2019). 
Protein Ligand docking 
Modelled ACE2 was docked with drugs retrieved from PubChem (Kim S et al, 2019), 
MOLBASE (www.molbase.com) and sketched structures. Chemical structures for 
Azithromycin (PubChem ID: 55185), Descladinose-azithromycin (PubChem ID: 71315587), 
Desethyl chloroquine (DCQ) (PubChem ID:95478), Desethyl hydroxychloroquine (PubChem 
ID:71826) and Hydroxychloroquine (HCQ) (PubChem ID:3652) were downloaded from 
PubChem database. 9a-N-desmethyl azithromycin with CAS NO: 76801-85-9 was downloaded 
from MOLBASE database, and bis desethyl hydroxychloroquine (BDCQ) was sketched using 
PUBCHEM Sketcher 2.4 (Ihlenfeldt et al., 2009). All the seven drug metabolites were 
considered for stable conformer generation using FRee Online druG conformation generation 
(FROG2) online server (Maria A et al, 2020). The input drug description used was SMILES 
(simplified molecular-input line-entry system) string and the output format was PDB with a 
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single product while the rest of the calculation parameters were set at default. AutoDock Tools 
1.5.6 was used for protein-ligand docking (Morris, G et al, 2009).  
Based on the literature review, the active site residues for ACE2 were Arg273, His345, Pro346, 
Glu375, His505 and Tyr515 (Tai W et al, 2020). Before docking, Kollman charges and 
Gasteiger charges were added to the protein and ligands respectively. The grid was centered 
within these six residues that form the active site. The size of the grid box was 70 Å, 64 Å and 
80Å for x, y and z respectively. Furthermore, the grid center was set to 2.250, 0.944 and 7.750 
for x, y and z respectively. AutoGrid 4.0 and AutoDock 4.0 programs were used to generate 
grid maps. The best ten conformers were generated using Lamarckian Genetic Algorithm. The 
binding energy and inhibition constant for each pose was calculated and the best selected poses 
were visualized using Discovery Studio Visualizer (Discovery Studio 2019).  
Results 
Multiple Sequence alignment 
S1 from INS1, INS2 and Wuhan SARS-CoV-2 protein sequences were considered for multiple 
sequence alignment using Clustal-Omega. The overall identity between S1 of INS1 and INS2 
was 99.84%. The overall identity between INS1 and Wuhan SARS-CoV-2 was 99.92 %. 
Tyr145 from INS1 and Wuhan SARS-CoV-2 is deleted in INS2 within the N-terminal domain 
(NTD). Similarly, Arg408 from INS1 and Wuhan SARS-CoV-2 is substituted by Ile in INS2 
(at position 407). Here, a positively charged residue is substituted by a hydrophobic residue 
within the RBD. Also, at position 929 in INS2 Val is substituted by Ala in INS1 and Wuhan 
SARS-CoV-2. In total, two substitutions and a single deletion was observed between these two 
sequences (Figure 1). Also, INS1, INS2 and Wuhan SARS-CoV-2 sequences were compared 
with SARS-CoV. Here we observed changes in the N-terminal domain and Receptor Binding 
Domain (Supplementary Figure 1). 
Homology modelling 
ACE2 sequence was considered as a query sequence in SWISS-MODEL to identify potential 
template. The crystal structure with PDB ID: 6m18 chain B was listed as a potential template 
with a query coverage of 99 % and 100 % amino acid identity. The generated model of ACE2 
had aa 21-768 which had both extracellular and helical domains. This complete model was 
validated using Ramachandran plot wherein the most favoured region was 91.4%; additional 
allowed region was 8.2%; generously allowed region was 0.4% and disallowed region was 0% 
6 
 
which confirmed that the structure was very stable (Figure 2a). The whole model had aa 21-
768 which is the combination of extracellular and helical domain of which, only the 
extracellular domain was retained (aa 21-740) by removing the helical domain which forms the 
complete ACE2 model. Furthermore, processed ACE2 was isolated (aa 21-708) to generate the 
sACE2 (Figure 3a).  
For S1, 6VSB chain A was listed as potential template with an amino acid identity of 99.17 % 
and a query coverage of 95% (Wrapp, D et al, 2020). All the domain details were obtained 
from literature review (Xia S et al, 2020). This generated model comprised of  aa  27-1146 
which forms complete S1 (aa 13-541) and partial S2 region (aa 778-1213) wherein the N-
terminal domain (NTD) was from aa 13-305; RBD from aa 319-436 and aa 509-541; RBM 
from aa 437-508; fusion peptide from aa 788-806 and the heptad repeat region1 from  aa 912-
984; the heptad repeat region 2 from aa 1163-1213 could not be modelled (Figure 3b). As per 
Ramachandran Plot, the most favoured region was 86.1%; additional allowed region was 
11.9%; generously allowed region was 1.7 and disallowed region was 0.3% (Figure 2b). When 
the RBD binding site was evaluated in INS1 and INS2 we observed that Arg 408 of INS1 
interacts with Asp405 and Thr376 resulting in a salt bridge and hydrogen bond within the RBD 
respectively. Interestingly, both these interactions are lost post substitution of Arg with Ile in 
INS2 (Figure 3c). 
 
Protein-Protein docking 
ACE2 was docked with the RBD of INS1 and INS2 which includes the RBM (described in 
Methods). The top cluster generated by HADDOCK was considered to reliable based on 
available literature. Higher HADDOCK dock score was observed between ACE2 and INS1 
compared to ACE2 and INS2. The buried surface area of INS1 was higher than INS2. Three 
salt bridges along with eleven hydrogen bonds were observed between complete ACE2 and 
INS1 (Figure 4a, b and Table 1). Furthermore, we observed the overall interface region of 
ACE2 which comes in close contact with INS1 and INS2. Interestingly, within ACE2 charged 
residues seem to play a critical role in these interactions. Of the ten interactions observed, seven 
were negatively charged while three were positively charged (Table 2).  Next, we analysed the 
interaction between complete ACE2 and INS2. There were three salt bridges observed between 
INS2 and ACE2 along with twelve hydrogen bonds.  Within the interface of ACE2 there were 
five negatively charged and five positively charged residues which come in direct contact with 
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INS2 (Figure 4b and Table 2). Docking of sACE2 with INS1 and INS2 (Figure 4c and d) 
showed that HADDOCK score of sACE2 with INS1 was higher than that of INS2 (Table 1).          
An increase in buried surface area was observed in INS1 compared to INS2. To ascribe 
biological relevance to the HADDOCK score it was further processed with PRODIGY online 
server to calculate binding energy. Reassuringly, we observed that HADDOCK scores were in 
concordance with the PRODIGY scores (Table 1). 
Further, interaction analysis between sACE2 and INS1 (Table 2) revealed two salt bridges and 
fourteen hydrogen bonds between INS1 and sACE2. The interface had seven negatively 
charged and three positively charged residues in direct contact. For interaction between sACE2 
with INS2, two salt bridges and eleven hydrogen bonds were observed.  Within sACE2, there 
were four negatively charged and three positively charged residues that were involved in 
interaction with INS2 (Table 2) (Figure 4c, d). Surface based analysis of ACE2 revealed that 
it has a relatively larger hydrophilic region and a smaller hydrophobic region available for S1 
interaction (Figure 5). 
 Protein -ligand docking 
In order to evaluate the binding affinity of actively considered therapeutic drugs and their active 
metabolites in the context of ACE2-S1 binding pocket, a local docking approach was 
employed. Azithromycin, Descladinose-azithromycin, 9a-N-desmethyl-azithromycin, 
Hydroxychloroquine (HCQ), Desethyl chloroquine, Desethyl hydroxychloroquine, and bis 
desethyl hydroxychloroquine were docked with ACE2 protein within the active site. 
Azithromycin and its active metabolites Descladinose-azithromycin and 9a-N-Desmethyl-
azithromycin showed better drug binding and inhibition constants compared to HCQ and its 
active metabolites (Figure 6a-c and Table 3). Amongst HCQ and its active metabolites, only 
bis desethyl hydroxychloroquine showed comparable (to Azithromycin) drug binding and 
inhibition constant (Figure 6d-g and Table 3). Negatively charged amino acids (on ACE2) 
Asp350, Asp382, Glu402 and Glu375 were preferred for all drug molecules except for HCQ 
which showed preference for positively charged amino acids (Arg393 and His401). 
Considering the proximity of the S1 binding site to the drug binding pocket of these compounds 
(Figure 3a), our results indicate the possibility of an allosteric modulation by these drugs.  
 
 
8 
 
Discussion 
In this study, we provide structural insights into the interaction between S1 and both soluble as 
well as full-length human ACE2 using the only two available viral sequences from India. Also, 
we elucidate the influence of potential therapeutics - Azythromycin and HCQ, together with 
their active metabolites, on the binding of S1 with ACE2. To begin with, we confirmed with 
Indian SARS-CoV-2 sequences that a stronger interaction with ACE2 exists compared to the 
SARS-CoV with ensuing implications for higher infection rates and transmission as has been 
reported recently (Chen Y, et al., 2020). A preliminary analysis of the two S1 sequences from 
India, that has witnessed introductions of the virus into the population from geographically 
distinct sources, reveals two substitutions and a single deletion. Interestingly, one of these 
substitutions is at position aa 407 within the RBD where a positively charged residue (Arg) is 
substituted by a hydrophobic residue (Ile). Other than obvious implications for virus-ACE2 
binding, we investigated whether this substitution would also affect soluble ACE2 and S1 
interaction. Our results show that INS1, most similar to the prototypical Chinese sequence 
(Supplementary Figure 1), had greater affinity for both forms of ACE2 compared to INS2. 
Intriguingly, INS2 and not INS1, seemed to show preferential affinity for sACE2. Further, the 
difference in affinities was lower when bound to sACE2. This has implications from both the 
co-morbidity as well as interventional perspective. Our results suggest that S1-ACE2 
complexes are stable and could potentially be systemically disseminated, more so in individuals 
with DM, HT and CV, resulting in higher co-morbidity and susceptibility to infection. Any 
vaccine generating neutralizing antibodies, for example, would need to disrupt these soluble 
complexes as well and conversely, if successful in doing so, would dramatically reduce 
susceptibility in vulnerable populations. 
The second major thrust of our study was to understand how potential therapeutics, being 
actively considered for widespread prophylactic and therapeutic intervention would affect 
virus-receptor interaction. Considering that an earlier report for SARS-CoV had suggested the 
possibility of such modulation (Martin JV, et al., 2005), we expanded our analysis to include 
active metabolites of these drugs. The drugs/metabolites evaluated were Azithromycin, 
Descladinose-azithromycin, 9a-N-desmethyl-azithromycin, Hydroxychloroquine, Desethyl 
chloroquine, Desethyl hydroxychloroquine, and bis desethyl hydroxychloroquine (BDCQ). We 
report for the first time that each of these compounds have the potential to allosterically 
modulate S1-ACE2 binding when studied using a protein-ligand approach. HCQ and its 
metabolites with the exception of BDCQ showed lower affinity and higher inhibitory constants 
compared to those of Azithromycin. Significantly, metabolites in general showed similar 
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binding affinity compared to their respective parent compounds. In fact, in the case of 
Hydroxychloroquine, BDCQ showed almost 30-fold better binding to ACE2 and this affinity 
was similar to that observed for Azithromycin. The lack of sequence information both globally 
and especially from India (Forster P, et al., 2020; Yadav P, et al., 2020) has limited our ability 
to robustly examine true consensus sequences for our analysis. Also, our insights need to be 
experimentally validated in vitro and in vivo. In conclusion, our results highlight a putative role 
of S1-sACE2 complexes in viral pathogenesis in susceptible populations. Further, we posit a 
direct role for ACE2 interacting drugs and other lead compounds (Goswami D, et al., 2020) in 
preventing infection, ameliorating viral carriage and eventually affecting transmission. 
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Figure legends 
 
Figure 1. Multiple sequence alignment of SARS-CoV-2 spike glycoprotein (S1) of Indian 
sequence 2 (MT012098.1), Indian sequence 1 (MT050493) and SARS-CoV2-WUHAN-
QHD43416. The Wuhan SARS-CoV-2 is sequentially identical to INS1 at N-terminal domain 
(NTD) and the RBD. Wuhan SARS-CoV-2 and INS2 is only identical at position 929 wherein 
valine is substituted by alanine. Comparing INS1 with INS2, a single indel was observed at 
position 145. Substitution of charged residue with hydrophobic residue was observed at 
position 407.  N-terminal Domain, RBD and RBM domains are highlighted in boxes. Deletion 
of tyrosine and substitution of arginine with isoleucine is highlighted by a downward arrow.  
Figure 2. The Ramachandran plot for the modelled proteins (a) ACE2 protein of Homo sapiens 
and (b) for SARS-CoV-2 Indian spike protein (S1). 
Figure 3. Homology model of human ACE2 and Indian SARS-CoV2 protein (a) Modelled 
ACE2 protein with domain details shown in ribbon file format. The extracellular domain 
comprises of green and pink colour. The helical domain is highlighted (blue) along with the 
soluble ACE2 protein (Dark green). SARS-COV-2 binding site is shown in surface format 
(cyan) and the drug binding site in sphere format (magenta) (b). The modelled Indian SARS-
COV-2 Spike glycoprotein S1 with the N-terminal domain (Yellow), RBD (Blue) and RBM 
(Green), fusion peptide (Cyan) and Heptad repeat 1 (Magenta) is displayed using ribbon 
format. (c) RBD binding site INS1 showing salt bridges of Arg 408 with Asp405 and Thr376 
Both these interactions are lost post substitution of Arg with Ile in INS2. 
Figure 4. Protein-protein docking (a) SARS-CoV-2 Indian sequence 1 with complete ACE2, 
(b) SARS-CoV-2 Indian sequence 2 with complete ACE2, (c) Indian sequence 1 with soluble 
ACE2 and (d) Indian sequence 2 with soluble ACE2. The orange colour represents the Indian 
SARS-CoV-2 protein and dark green colour represents ACE2 protein.  
Figure 5. Surface view of ACE2 protein depicting the protein-protein binding site. The blue 
colour depicts the hydrophilic region and the red depicts the hydrophobic region.  
Figure 6. Protein-ligand docking of soluble ACE2 with (a) Azithromycin, (b) Descladinose-
azithromycin, (c) 9a-N-Desmethyl-azithromycin, (d) Hydroxychloroquine, (e) Desethyl 
chloroquine, (f) Desethyl hydroxychloroquine, (g) Bisdesethyl hydroxychloroquine.                
The soluble ACE2 protein is shown in ribbon format in green colour, sidechains are shown in 
magenta and the drug in orange colour.  
Supplementary Figure 1. Multiple sequence alignment of SARS-CoV-2 spike glycoprotein 
(S1) of SARS-CoV-NP_828851.1 (SARS-CoV-2003), Indian sequence 2 (MT012098.1), 
Indian sequence 1 (MT050493) and SARS-CoV2-WUHAN-QHD43416.  
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Figure 1. Multiple sequence alignment of SARS-CoV-2 spike glycoprotein (S1) of Indian 
sequence 2 (MT012098.1), Indian sequence 1 (MT050493) and SARS-CoV2-WUHAN-
QHD43416. The Wuhan SARS-CoV-2 is sequentially identical to INS1 at N-terminal domain 
(NTD) and the RBD. Wuhan SARS-CoV-2 and INS2 is only identical at position 929 wherein 
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Figure 2. The Ramachandran plot for the modelled proteins (a) ACE2 protein of Homo sapiens 
and (b) for SARS-CoV-2 Indian spike protein (S1). 
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Figure 3. Homology model of human ACE2 and Indian SARS-CoV2 protein (a) Modelled 
ACE2 protein with domain details shown in ribbon file format. The extracellular domain 
comprises of green and pink colour. The helical domain is highlighted (blue) along with the 
soluble ACE2 protein (Dark green). SARS-COV-2 binding site is shown in surface format 
(cyan) and the drug binding site in sphere format (magenta) (b). The modelled Indian SARS-
COV-2 Spike glycoprotein S1 with the N-terminal domain (Yellow), RBD (Blue) and RBM 
(Green), fusion peptide (Cyan) and Heptad repeat 1 (Magenta) is displayed using ribbon 
format. (c) RBD binding site INS1 showing salt bridges of Arg 408 with Asp405 and Thr376 
Both these interactions are lost post substitution of Arg with Ile in INS2. 
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Figure 4. Protein-protein docking (a) SARS-CoV-2 Indian sequence 1 with complete ACE2, 
(b) SARS-CoV-2 Indian sequence 2 with complete ACE2, (c) Indian sequence 1 with soluble 
ACE2 and (d) Indian sequence 2 with soluble ACE2. The orange colour represents the Indian 
SARS-CoV-2 protein and dark green colour represents ACE2 protein.  
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Figure 5. Surface view of ACE2 protein depicting the protein-protein binding site. The blue 
colour depicts the hydrophilic region and the red depicts the hydrophobic region.  
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Figure 6. Protein-ligand docking of soluble ACE2 with (a) Azithromycin, (b) Descladinose-
azithromycin, (c) 9a-N-Desmethyl-azithromycin, (d) Hydroxychloroquine, (e) Desethyl 
chloroquine, (f) Desethyl hydroxychloroquine, (g) Bisdesethyl hydroxychloroquine.                
The soluble ACE2 protein is shown in ribbon format in green colour, sidechains are shown in 
magenta and the drug in orange colour.  
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Table 1. Protein-protein docking using HADDOCK online software wherein  
binding affinity was calculated using PRODIGY server. 
 
SARS-CoV S1 -ACE2 
interactions 
HADDOCK values 
 
PRODIGY 
values 
kcal/mol HADDOCK 
score 
Buried surface 
Area (Å2) 
SARS-CoV with ACE2 -165.1 +/-12.2 2896.2 +/- 450.1 -10.3 
INS1 (MT050493) with 
ACE2 
-178.6 +/-7.7 3706.2 +/- 130.8 -18.1 
INS2 (MT012098.1) 
 with ACE2 
-112.3 +/-17.9 3475.5 +/- 361.5 -14.7 
INS1(MT050493) with 
sACE2 
-168.2 +/-8.7 3756.5 +/- 96.1 -18.0 
INS2(MT012098.1) with 
sACE2 
-121.1 +/-6.6 3160.1 +/-178.2 -16.9 
 
 
Table 2. Interaction between INS 1 and 2 with ACE2 and sACE2. 
 
Docking Indian SARS-COV-2  
S1 Sequences 
ACE2 Number of salt 
bridges  
INS1 
with 
ACE2 
Ile332, Asn334, Asn354, 
Lys356, Arg357, Ser399, 
Cys480, Ala352, Trp353, 
Asp398, Thr470 
Glu329, Asp355, Phe356, 
Asp30, Asn33, Glu37, 
Asp38, Glu75, Lys31, 
His34, Tyr83, Asn330 
3 
Lys356: Glu37 
Arg357: Asp38 
Asp398: His34 
INS2 
with 
ACE2 
Asn333, Thr344, Arg345, 
Asn353, Lys355, Arg356, 
Asn449, Asn480, Val444, 
Glu470, Cys479, Asn393, 
Trp352, Glu339 
Gly319, Ala387, Asp30, 
Glu37, Ala386, Asp355, 
Gln42, Lys26, His34, 
Lys68, Gln325, Lys353 
3 
Arg345: Asp30 
Arg356: Asp355 
Glu470: Lys68 
INS1 
with 
sACE2 
Ile332, Asn334, Asn354, 
Lys356, Arg357, Tyr473, 
Cys480, Gln580, Glu471, 
Asn450, Trp353, Ser359 
Glu329, Gly354, Asp355, 
Asp30, Glu37, Asp38, 
Gln42, Lys31, Glu75, 
Ile21, Thr27, Thr324, 
Asn330, Lys353 
2 
Lys356: Glu37 
Arg357: Asp38 
INS2 
with 
sACE2 
Ser348, Asn353, Lys355, 
Ser358, Asn480, Tyr448, 
Asp441, Trp352, Ser468, 
Glu339, Ser398 
Asp38, Asp355, Asn330, 
Asp67, Lys31, His34, 
Gln42, Lys68, Thr324, 
Lys353, Phe356 
2 
Lys355: Asp355 
Asp441: His34 
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Table 3. Protein-ligand docking for sACE2 interaction with Azithromycin,  
Hydroxychloroquine and their respective metabolites. 
 
Chemical Compounds 
 
Binding affinity 
(kcal/mol) 
Inhibitory constant 
(μM) 
Azithromycin -7.7 2.0 
Descladinose 
 
-8.03 1.3 
9a-N-Desmethyl 
 
-7.43 3.55 
 
Hydroxychloroquine 
-5.75 60.78 
Desethyl chloroquine (DCQ) 
 
-6.97 7.81 
Desethyl hydroxychloroquine 
 
-6.71 12.13 
Bidesethyl 
hydroxychloroquine(BDCQ) 
 
-7.62 2.62 
To determine if the interaction was specific to the drugs, Pencillin structure was downloaded 
from PDB (id: PDB IFXV) and docked with sACE2. We observed a binding energy of  -4.36 
kcal/mol and an inhibitory constant value of 642.05 μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
Supplementary Figure 1. Multiple sequence alignment of SARS-CoV-2 spike glycoprotein 
(S1) of SARS-CoV-NP_828851.1 (SARS-CoV-2003), Indian sequence 2 (MT012098.1), 
Indian sequence 1 (MT050493) and SARS-CoV2-WUHAN-QHD43416.  
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